



IFW

Atty. Dkt. No. 355491-1250

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christopher D. ROBERTS, et al.

Title: NUCLEOSIDE DERIVATIVES
FOR TREATING HEPATITIS C
VIRUS INFECTION

Appl. No.: 10/676,956

Filing Date: 9/30/2003

Examiner: Unassigned

Art Unit: 1623

<p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p>_____ Esther Lily C. Esguerra (Printed Name)</p> <p>_____ <i>[Signature]</i> (Signature)</p> <p>_____ June 23, 2004 (Date of Deposit)</p>

**STATEMENT TO SUPPORT FILING AND SUBMISSION OF
SEQUENCE LISTING CORRECTION**

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This application shows two DNA primer sequences on page 88. These sequences do not appear in the claims.

A sequence listing was submitted in paper and electronic form on September 30, 2004. It was received by the OIPE and a correction was requested and satisfied on February 4, 2004.

Unfortunately, no one noticed that while the sequence shown in the specification is a DNA sequence, the paper and electronic form previously submitted and corrected is an Amino Acid Sequence.

We need to fix this.

We now submit three items.

1. A new paper sequence listing.
2. A "red marked" copy of the corrected sequence listing. This shows that the amino

acids are now replaced with nucleosides. In addition, the preparers of the new sequence listing made some minor editorial corrections to the written text.

3. A computer-readable form of the correct listing in Patent In Ver. 3.2.


In connection with the Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 CFR §1.821(g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

By 

Julie L. Heinrich, Ph.D.
Agent for Applicants
Registration No. 48,070

Date: June 23, 2004

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 856-3700
Facsimile: (650) 856-3710